Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Sales Agreement filed with SEC - 186 pages

<< Previous

Bullboard Posts

Next >>

Comment by BlueJays9293on Aug 14, 2024 7:21pm

101 Views

Post# 36179555

RE:RE:RE:Sales Agreement filed with SEC - 186 pages

I could be wrong, but I read that as referring to Toth's employment as an executive for Baxter. Sounds like his Long Term Incentive Plan with Baxter will vest according to the terms of his Baxter executive agreement.

It's very unclear what the meaning of that paragraph is so it wouldn't surprise me if Carlyle Group put in their own person to lead Vantive and it also wouldn't surprise me if they kept on Toth because he's so familiar with the kidney division. If Carlyle views Toth as a mini clone of the Baxter CEO then they will surely want to replace him.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale